Amar U Kishan: Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer
Amar U Kishan, Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA, shared a post by UCLA Jonsson Comprehensive Cancer Center on X, adding:
“Proud to share this work out in AACR Clinical Cancer Research where in we validity the ability of PROSTOX to predict late GU toxicity following SBRT. This test, based on SNPs in microRNAs, shows a robust AUC for late grade 2 or greater toxicity.
It is easy to obtain this via a simple cheek swab (or any other method that allows assessment of germline DNA). We also show that the drivers of acute, late, and chronic (persistent acute) stem from distinct pathways.
We eagerly await the results of our prospective GARUDA trial as well as other ongoing validation efforts in distinct trial cohorts.”
Quoting UCLA Jonsson Comprehensive Cancer Center‘s post:
“New study published in AACR Clinical Cancer Research, led by Amar U Kishan and Joanne Weidhaas, validates a first-of-its-kind genetic test that predicts which prostate cancer patients are most likely to develop long-term urinary side effects from radiation therapy. More here.”
Authors: Amar U Kishan et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023